Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$4.95 USD
-0.03 (-0.60%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $4.94 -0.01 (-0.20%) 6:42 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Abeona Therapeutics Inc. [ABEO]
Reports for Purchase
Showing records 1 - 20 ( 89 total )
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Non-Exclusive Agreement With Beacon Therapeutics Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Revolutionizing Therapy for Butterfly Children; Initiating at Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Significantly Undervalued Approaching Pivotal Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
REGENXBio Settlement Reached; 3Q21 Financials; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Leadership Changes Announced; Pipeline Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Favorable ABO-102 Type B Meeting With FDA; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Adverse Arbitration Ruling Received; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
EB-101 Phase 1/2 Long-Term Efficacy Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Clinical Development Update; R&D Chief Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Clarity From Arbitration Tribunal; 2020 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neurocognitive Development Preservation Interim Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Risks; Financial Results Reported; Reducing PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ABO-202 Licensing Agreement Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
EB-101 VIITAL Phase 3 Trial Proceeding; 2Q20 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Society for Pediatric Dermatology Meeting Posters; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VIITAL Pivotal Study Enrollment Resumes; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financials Reported; Pivotal EB-101 Trial Ongoing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Disruption Transience; EB-101 Trial Ongoing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R